Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection

Theodoros Kelesidis, Judith S. Currier, Otto O. Yang, Todd T. Brown

Research output: Contribution to journalReview articlepeer-review

Abstract

Patients with HIV-1 infection often develop multiple complications and comorbidities, including osteoporosis and atherosclerosis. The receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand/osteoprotegerin axis has been identified as a possible common link between osteoporosis and vascular diseases. Since the discovery of this axis, much has been learned about its role in controlling skeletal biology and less about its role in the context of vascular biology. However, the exact role of the receptor activator of nuclear factor kappa-B ligand/osteoprotegerin axis in HIV infection is not completely understood. In this review we examine the mechanisms by which inflammation and immune dysregulation in HIV-1 infection may impact bone turnover and atherogenesis through perturbations in the receptor activator of nuclear factor kappa-B/receptor activator of nuclear factor kappa-B ligand/osteoprotegerin axis.

Original languageEnglish (US)
Pages (from-to)123-133
Number of pages11
JournalAIDS Reviews
Volume16
Issue number3
StatePublished - Jul 1 2014

Keywords

  • Bone
  • Cardiovascular disease
  • HIV
  • Immunity
  • Osteoprotegerin
  • RANK ligand

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection'. Together they form a unique fingerprint.

Cite this